Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

Impact · against what's priced in

The agreement provides a concrete financial boost to Regeneron via a $1B upfront payment, though the long-term pipeline expansion is partially offset by the 2027 delay for most candidates. For Sanofi, the deal secures a next-generation immunology pipeline and resolves legal friction, though the immediate financial cost is a headwind.

REGN+0.30: Not in the price yet
The price assumes: Any upside from the olatorepatide obesity and diabetes studies, which the market treats as a free option

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

What matters in this story

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

What matters in this story

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

How each ticker is affected

Connected tickers

Track these names every morning.

Can The Hartford's Equitable Deal Strengthen Its Benefits Business?

Walmart Stock Moves Higher: What's Happening?

Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

BBNX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

What matters in this story

Next reads from the same story arc

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

What matters in this story

Next reads from the same story arc

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

How each ticker is affected

Connected tickers

Track these names every morning.

Can The Hartford's Equitable Deal Strengthen Its Benefits Business?

Walmart Stock Moves Higher: What's Happening?

Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

BBNX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BBNX